Gene · 9294
S1PR2: sphingosine-1-phosphate receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. S1PR2: sphingosine-1-phosphate receptor 2. Genes, record 9294. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9294
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95136 | Sphingosine 1-phosphate receptor 2 | 353 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 65285 | O95136 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 19527 | O95136 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 4037 | O95136 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 25134 | O95136 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3811 | O95136 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3811 | O95136 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 4037 | O95136 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 25134 | O95136 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 19527 | O95136 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 16056 | O95136 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMISELIMOD | CHEMBL3707375 | Sphingosine 1-phosphate receptor modulator | MODULATOR | ChEMBL |
| AMISELIMOD HYDROCHLORIDE | CHEMBL3707374 | Sphingosine 1-phosphate receptor modulator | MODULATOR | ChEMBL |
| FINGOLIMOD | CHEMBL314854 | Sphingosine 1-phosphate receptor agonist | AGONIST | ChEMBL |
| FINGOLIMOD | CHEMBL314854 | Sphingosine 1-phosphate receptor binding agent | BINDING AGENT | ChEMBL |
| FINGOLIMOD HYDROCHLORIDE | CHEMBL544665 | Sphingosine 1-phosphate receptor agonist | AGONIST | ChEMBL |
| FINGOLIMOD LAURYL SULFATE | CHEMBL5095050 | Sphingosine 1-phosphate receptor binding agent | BINDING AGENT | ChEMBL |
Trials83
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07483632 | FINGOLIMOD | PHASE3 | ClinicalTrials.gov | |
| NCT07220252 | FINGOLIMOD | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06424067 | FINGOLIMOD | PHASE2 | ClinicalTrials.gov | |
| NCT06408259 | FINGOLIMOD | PHASE3 | ClinicalTrials.gov | |
| NCT06087965 | FINGOLIMOD | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05762003 | FINGOLIMOD | ClinicalTrials.gov | ||
| NCT05423769 | FINGOLIMOD | ClinicalTrials.gov | ||
| NCT05141669 | FINGOLIMOD | ClinicalTrials.gov | ||
| NCT05123703 | FINGOLIMOD | PHASE3 | ClinicalTrials.gov | |
| NCT04857112 | AMISELIMOD | PHASE2 | ClinicalTrials.gov |
1 to 10 of 83
See all 83 trialsNIH grants1,282
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | S1PR2 papers | Newest fiscal year |
|---|---|---|---|
| P01CA097132 | Sphingolipids in Cancer Biology and Therapy | 19 | 2025 |
| P30CA016059 | Massey Cancer Center - Cancer Center Support Grant | 10 | 2025 |
| IK6BX004477 | BLR&D Research Career Scientist Award Application | 7 | 2025 |
| P30CA138313 | Medical University of South Carolina - Cancer Center Support Grant | 7 | 2025 |
| P01HL126609 | Cytoskeletal Regulation of Lung Endothelial Pathobiology in ARDS | 6 | 2025 |
| R01DE016572 | Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| R01AI040098 | B lymphocyte Migration and Homeostasis | 5 | 2025 |
| ZIADK056014 | Mouse Models of Novel Sphingolipid Biology and Disease Mechanisms | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,282Source NIH's project files
See all 1,282 nih grantsPapers2,171
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bile acid signaling in health and disease. | Mol Biomed | 2026 | 42825856 | PubTator, text mining | PubMed |
| Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access. | Front Drug Deliv | 2026 | 42756066 | PubTator, text mining | PubMed |
| Sphingosine 1-phosphate signalling contributes to transforming growth factor-β1-induced myofibroblast differentiation in oral cancer. | PeerJ | 2026 | 42730290 | PubTator, text mining | PubMed |
| Decoding the bile acid-mitochondria axis: Implications for disease management and therapeutic opportunities. | Pharmacol Res | 2026 | 42668075 | PubTator, text mining | PubMed |
| JTE-013 ameliorates allergic asthma by targeting the S1PR2-HDAC3-p53 signaling axis to improve mitochondrial homeostasis. | Int Immunopharmacol | 2026 | 42574803 | PubTator, text mining | PubMed |
| The role and mechanism of S1PR2 in endothelial dysfunction and aortic lesions during gestational diabetes mellitus. | Placenta | 2026 | 42526136 | PubTator, text mining | PubMed |
| α-fluoro-β-alanine functions as a β-arrestin1-biased ligand of S1PR2 to upregulate DPD expression in cancer cells. | Proc Natl Acad Sci U S A | 2026 | 42475555 | PubTator, text mining | PubMed |
Extracellular vesicles from plasma of patients with minimal hepatic encephalopathy induce neuroinflammation and cognitive impairment in rats, which are prevented by treating the patients with rifaximin. | J Neuroinflammation | 2026 | 42343379 | PubTator, text mining | PubMed |
| The interplay between bile acid metabolism and gut microbiome in biliary tract cancers. | Front Microbiomes | 2026 | 42293159 | PubTator, text mining | PubMed |
| PET Imaging Characterization of Sphingosine-1-Phosphate Receptor 2 in a Mouse Model of Esophageal Adenocarcinoma and Metastatic Lymph Node. | Mol Pharm | 2026 | 42250214 | PubTator, text mining | PubMed |
1 to 10 of 2,171
See all 2,171 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9294
GET https://conductscience.org/api/genes/v1/9294/patents?page=2